Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems, Inc. (NYSE: INSP) reported strong third-quarter results for 2020, with revenues of $35.8 million, marking a 72% year-over-year increase. Gross margin improved to 85.5%, up from 83.4% last year. The company activated 42 new medical centers, exceeding prior guidance, and created seven new sales territories. Inspire raised its full-year revenue guidance to $110 million to $112 million from a prior estimate of $88 million to $92 million, driven by increased patient flow and effective coverage policies.
MINNEAPOLIS, Oct. 27, 2020 – Inspire Medical Systems (NYSE: INSP) announced its management team will present at the Credit Suisse 29th Annual Healthcare Conference on November 10, 2020, at 11:00 a.m. Eastern Time. The presentation will be accessible via a live webcast. Inspire specializes in developing innovative, minimally invasive solutions for obstructive sleep apnea, and its Inspire therapy is the first FDA-approved neurostimulation treatment for this condition. A replay of the presentation will be available for two weeks on Inspire’s investor website.
On October 22, 2020, Inspire Medical Systems (NYSE: INSP) announced the appointment of Shelley Broader to its Board of Directors. Broader, with extensive experience in global leadership at major brands like Walmart and Chico's FAS, will enhance the board's focus as the company grows. Additionally, Chau Khuong will retire from the board at the end of October. Tim Herbert, CEO, emphasized the importance of Broader's experience in shaping Inspire's commercial strategy.
Inspire Medical Systems, Inc. (NYSE: INSP) will release its third quarter 2020 financial results on November 2, 2020, post-market close. A conference call to discuss these results and recent business developments will begin at 5:00 PM Eastern Time. Inspire specializes in innovative solutions for obstructive sleep apnea, with its Inspire therapy being the first FDA-approved neurostimulation technology for moderate to severe cases. Details for joining the call and further information about the company are provided in the release.
Inspire Medical Systems announced that two additional Blue Cross Blue Shield plans, Florida Blue and BCBS Minnesota, will now cover the company's Inspire therapy for obstructive sleep apnea. This decision expands coverage to approximately 8.6 million members, bringing the total to 31 BCBS plans covering Inspire therapy, affecting over 190 million lives. With an effective date of August 15, 2020, for Florida Blue and October 5, 2020, for BCBS Minnesota, Inspire therapy also has Medicare coverage across the U.S..
Inspire Medical Systems, Inc. (NYSE: INSP) has received approval from the Australian Therapeutic Goods Administration (TGA) for its Inspire therapy targeting moderate to severe obstructive sleep apnea (OSA) in patients unable to use CPAP. OSA affects about 5% of Australians, with around one million qualifying as moderate to severe cases. The company is now pursuing reimbursement approval from the Medical Services Advisory Committee (MSAC) and expects to launch its therapy in Australia post-2021. CEO Tim Herbert emphasizes the therapy's strong clinical evidence supporting its safety and efficacy.
Inspire Medical Systems (NYSE: INSP) announced the appointment of Georgia Garinois-Melenikiotou to its Board of Directors, enhancing its leadership with her extensive experience in global consumer marketing and corporate management. Mudit Jain, a founding partner and board member since 2009, will retire at the end of July 2020. CEO Tim Herbert emphasized the importance of diverse expertise for future growth, highlighting Ms. Garinois-Melenikiotou's potential contributions to innovative marketing strategies for Inspire's FDA-approved neurostimulation therapy targeting obstructive sleep apnea.
Inspire Medical Systems, Inc. (NYSE: INSP) plans to release its second quarter 2020 financial results on August 4, following the market close. A conference call will start at 5:00 PM ET to discuss the results and recent business developments. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, including its FDA-approved neurostimulation technology. For information, visit www.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) announced that Cigna will provide coverage for its Inspire therapy, effective June 15, 2020. This brings the total coverage to 54 policies, now covering over 180 million members, up from 83 million last year. Additionally, Inspire therapy is set to receive Medicare coverage across the U.S. Cigna's policy deems the FDA-approved device medically necessary for treating moderate to severe obstructive sleep apnea under specific conditions. The company anticipates accelerated growth post-COVID-19 due to these developments.
Inspire Medical Systems (NYSE: INSP) has launched the new Inspire Sleep app, aimed at enhancing patient management for obstructive sleep apnea. This app facilitates telemedicine consultations and follow-up care, meeting the needs of patients and medical practices during challenging times. The app, available on Google Play and the Apple App Store, allows patients to learn about Inspire therapy and connect with trained physicians. Future updates will include clinical data collection and improved patient adherence tracking. Inspire continues to innovate in digital health solutions for better patient outcomes.